Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 5/20 | 0.39 |
| ▸ | RXRB | P28702 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394064 | 0.91 | RXRA (0.39) | L3MBTL1TDP1RXRARXRBLMNA | |
| SCHEMBL2471654 | 0.83 | L3MBTL1 (0.43) | L3MBTL1TDP1LMNAMAPK1ATM | |
| SCHEMBL2472830 | 0.83 | ESR1 (0.42) | L3MBTL1TDP1MAPTNPSR1ALDH1A1 | |
| SCHEMBL2469489 | 0.81 | MAPK1 (0.41) | L3MBTL1TDP1LMNAMAPK1ATM | |
| SCHEMBL2470341 | 0.81 | L3MBTL1 (0.58) | L3MBTL1TDP1LMNAMAPK1ATM | |
| SCHEMBL2499179 | 0.81 | EGLN1 (0.43) | RXRARXRBRXRG | |
| SCHEMBL2469965 | 0.81 | RPS6KB1 (0.46) | L3MBTL1TDP1LMNAMAPK1ATM | |
| SCHEMBL2471545 | 0.78 | LMNA (0.41) | L3MBTL1TDP1LMNAMAPK1ATM | |
| SCHEMBL2472066 | 0.76 | RXRA (0.38) | RXRARXRBRXRGICMT | |
| SCHEMBL2474452 | 0.76 | LMNA (0.44) | L3MBTL1TDP1LMNAMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | L3MBTL1 2997/4885TDP1 2259/4885RXRA 2557/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | L3MBTL1 2997/4885TDP1 2259/4885RXRA 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.